Second-line (2L) treatment patterns and clinical outcomes among real-world (RW) patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP) in the first-line (1L)

被引：0

作者：

Paluri, Ravi Kumar

Silver, Michelle

Cockrum, Paul

Dennen, Syvart

机构：

[1] Wake Forest Univ, Winston Salem, NC USA

[2] Genesis Res Grp, Hoboken, NJ USA

[3] Ipsen Biopharmaceut Inc, Cambridge, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e16322

引用

页数：1

共 50 条

[1] Adverse events in real-world patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX (FFX) or gemcitabine with nab-paclitaxel (GnP) in the first line (1L)
Dennen, Syvart
Silver, Michelle
Cockrum, Paul
Paluri, Ravi Kumar
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] Treatment outcomes with first-line (1L) nab-Paclitaxel plus gemcitabine (AG) and FOLFIRINOX (FFX) in metastatic pancreatic adenocarcinoma (mPAC).
Cartwright, Thomas H.
Parisi, Monika
Espirito, Janet L.
Wilson, Thomas
Pelletier, Corey
Patel, Manish
Babiker, Hani M.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[3] PREDICTORS OF OVERALL SURVIVAL (OS) AND TIME TO NEXT TREATMENT (TTNT) IN REAL-WORLD METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (mPDAC) PATIENTS WHO RECEIVED FIRST-LINE (1L) FOLFIRINOX (FFX) OR GEMCITABINE plus NAB-PACLITAXEL (GnP)
Dennen, S.
Silver, M.
Cockrum, P.
Kim, G. P.
VALUE IN HEALTH, 2024, 27 (06) : S22 - S22
[4] Real-world excess costs associated with hematologic adverse events (hAEs) during first-line (1L) treatment of metastatic pancreatic adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), FFX without 5FU bolus, and gemcitabine plus nab-paclitaxel (GnP).
Dennen, Syvart
Masek, Marty
Cockrum, Paul
Paluri, Ravi Kumar
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 693 - 693
[5] Real-world use of supportive medications to prevent and manage key adverse events during first-line (1L) treatment of metastatic pancreatic adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), FFX without 5FU bolus, and gemcitabine plus nab-paclitaxel (GnP)
Dennen, Syvart
Masek, Marty
Cockrum, Paul
Paluri, Ravi Kumar
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 695 - 695
[6] Costs of generic vs. branded nab-paclitaxel (nP) during first-line (1L) treatment of metastatic pancreatic adenocarcinoma (mPDAC) with gemcitabine plus nab-paclitaxel (GnP) in a real-world commercial database.
Dennen, Syvart
Masek, Marty
Naga, Sai Sriteja Boppudi
Cockrum, Paul
Paluri, Ravi Kumar
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
[7] Real-world dose intensity (DI) and time to adverse events (AEs) in a commercial database during first-line (1L) treatment of metastatic pancreatic adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), FFX without 5FU bolus, and gemcitabine plus nab-paclitaxel (GnP).
Dennen, Syvart
Masek, Marty
Cockrum, Paul
Paluri, Ravi Kumar
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 692 - 692
[8] Second-line treatment of modified FOLFIRINOX or nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma
Ozaka, Masato
Sasaki, Takashi
Yamada, Ikuhiro
Kanata, Ryo
Akiyama, Dai
Katagiri, Tomoko
Takano, Koichi
Matsuyama, Masato
Sasahira, Naoki
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[9] First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population
Hatashima, Alycia
Arango, Matthew J.
Reardon, Joshua
Freeman, Tracelyn
Williams, Terence
McLaughlin, Eric M.
Abushahin, Laith
FUTURE ONCOLOGY, 2022, 18 (20) : 2521 - 2532
[10] Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
Klein-Brill, Avital
Amar-Farkash, Shlomit
Lawrence, Gabriella
Collisson, Eric A.
Aran, Dvir
JAMA NETWORK OPEN, 2022, 5 (06) : E2216199

← 1 2 3 4 5 →